Skip to content

Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing

Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07319923
Enrollment
3000
Registered
2026-01-06
Start date
2024-01-01
Completion date
2027-12-01
Last updated
2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-based Screening, Prostate Cancer

Brief summary

Prostate cancer is one of the most common malignancies in the male genitourinary system, and it is also the cancer with the fastest-growing incidence and mortality rates among men in China. Although prostate cancer screening can significantly reduce mortality, China has not yet established a well-developed screening system, which is one of the reasons why its mortality rate remains notably higher than that of Western countries. The primary objective of this project is to establish an efficient screening-diagnosis-treatment pathway, beginning with screening in community hospitals, followed by definitive diagnosis in secondary hospitals, and finally treatment in tertiary hospitals. Additionally, the project aims to achieve multi-institutional and multi-terminal sharing of disease information as well as dynamic monitoring and follow-up. The feasibility and effectiveness of this model will be validated through statistical analysis of the data.

Interventions

OTHERNo intervention

No intervention

Sponsors

Peking University First Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

* Male community residents aged 50 years or older; Life expectancy \> 10 years and ECOG performance status of 0-2; Permanent residents of Beijing who are willing to cooperate with researchers in the screening process, complete required tests and questionnaires, and participate in subsequent follow-up; Support for the research project and provision of signed informed consent.

Exclusion criteria

* 1)Presence of any other malignant tumor or pre-existing prostate malignancy; 2)Presence of prostatitis or active infection in other parts of the urinary system; 3)Inability to cooperate with the study procedures or other factors deemed unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Serum PSA levelfrom 2025 to 2027

Countries

China

Contacts

Primary ContactZejin Ou
1522065106@qq.com17310018392

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026